Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 621 to 630 of 1443 total matches.
Glyxambi - A New Combination for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Apr 27, 2015 (Issue 1467)
. All rights reserved. ©2015. www.fdbhealth.com/policies/drug-pricing-policy.
66
The Medical Letter ® Vol. 57 ...
The FDA has approved Glyxambi (Boehringer
Ingelheim/Lilly), a fixed-dose combination of empagliflozin
(Jardiance) and linagliptin (Tradjenta), for oral
treatment of type 2 diabetes in adults. It is the first
combination of a sodium-glucose co-transporter 2
(SGLT2) inhibitor and a dipeptidyl peptidase-4 (DPP-4) inhibitor to be approved in the US.
Netupitant/Palonosetron (Akynzeo) for Chemotherapy-Induced Nausea and Vomiting
The Medical Letter on Drugs and Therapeutics • Apr 27, 2015 (Issue 1467)
).
62
The Medical Letter ® Vol. 57 (1467) April 27, 2015
undergoing highly emetogenic (cisplatin-based ...
The FDA has approved Akynzeo (Helsinn/Eisai), an oral
fixed-dose combination of the substance P/neurokinin
1 (NK1) receptor antagonist netupitant and the
serotonin-3 (5-HT3) receptor antagonist palonosetron,
for prevention of acute and delayed nausea and
vomiting associated with cancer chemotherapy
in adults. Akynzeo is the first product to combine
drugs from these two classes. Palonosetron (Aloxi)
is also available as a single agent for prevention of
chemotherapy-induced and postoperative nausea
and vomiting. Netupitant is the second substance
P/NK1 receptor antagonist to be...
Umeclidinium (Incruse Ellipta) for COPD
The Medical Letter on Drugs and Therapeutics • Apr 27, 2015 (Issue 1467)
The Medical Letter ® Vol. 57 (1467) April 27, 2015
PREGNANCY — Umeclidinium is classified as category
C ...
The FDA has approved Incruse Ellipta (GSK), a
single-agent inhaler containing the long-acting
anticholinergic umeclidinium, for once-daily maintenance
treatment of chronic obstructive pulmonary
disease (COPD). Umeclidinium was initially approved
in combination with the long-acting beta2-adrenergic
agonist vilanterol as Anoro Ellipta.
Belinostat (Beleodaq) for Peripheral T-Cell Lymphoma (online only)
The Medical Letter on Drugs and Therapeutics • Apr 27, 2015 (Issue 1467)
The Medical Letter ® Vol. 57 (1467) April 27, 2015
1. Pralatrexate (Folotyn) for peripheral T-cell lymphoma ...
The FDA has approved belinostat (Beleodaq –
Spectrum), an IV histone deacetylase (HDAC)
inhibitor, for treatment of adults with relapsed or
refractory peripheral T-cell lymphoma (PTCL). It is
the third IV drug approved by the FDA for PTCL. The
first was the antifolate drug pralatrexate (Folotyn),
which was followed by the HDAC inhibitor romidepsin
(Istodax). Vorinostat (Zolinza), an oral HDAC
inhibitor, is FDA-approved for treatment of cutaneous
T-cell lymphoma.
Pomalidomide (Pomalyst) for Multiple Myeloma (online only)
The Medical Letter on Drugs and Therapeutics • Apr 27, 2015 (Issue 1467)
-2769
e67
The Medical Letter ® Vol. 57 (1467) April 27, 2015
respiratory tract infection ...
The FDA has approved pomalidomide (Pomalyst –
Celgene), an oral thalidomide analog, for treatment
of patients with multiple myeloma who have received
at least 2 prior therapies including lenalidomide
(Revlimid) and bortezomib (Velcade) and whose
disease had progressed on or within 60 days of
completion of the last therapy.
Ivermectin Cream (Soolantra) for Rosacea
The Medical Letter on Drugs and Therapeutics • Apr 13, 2015 (Issue 1466)
to topical antimicrobials. The oral retinoidThe Medical Letter ® Vol. 57 (1466) \
as category C (evidence ...
The FDA has approved a 1% cream formulation
of the antiparasitic drug ivermectin (Soolantra –
Galderma) for topical treatment of inflammatory
lesions of rosacea. Ivermectin is available in the US
in tablets (Stromectol, and generics) for treatment of
onchocerciasis and other worm infestations and as a
0.5% lotion (Sklice) for treatment of head lice.
Gardasil 9 - A Broader HPV Vaccine
The Medical Letter on Drugs and Therapeutics • Mar 30, 2015 (Issue 1465)
or 10 single-dose vials or 10 single-dose prefilled syringes.
48
The Medical Letter ® Vol. 57 (1465 ...
The FDA has now approved a recombinant, 9-valent,
human papillomavirus (HPV) vaccine (Gardasil 9 –
Merck) for use in girls and women 9-26 years old and
boys 9-15 years old. The new vaccine is indicated to
prevent diseases associated with infection with HPV
types 6, 11, 16, 18, 31, 33, 45, 52, and 58, which include
genital warts and cervical, vulvar, vaginal, and anal
precancerous lesions and cancer. Two recombinant
HPV vaccines are already available in the US: Gardasil
prevents disease associated with HPV types 6, 11, 16,
and 18, and Cervarix prevents disease associated
with HPV...
OTC Fluticasone Nasal Spray for Allergic Rhinitis
The Medical Letter on Drugs and Therapeutics • Mar 30, 2015 (Issue 1465)
are absorbed systemically.
Older agents such as triamcinolone acetonide may be
49
The Medical Letter ® Vol ...
The nasal spray formulation of the corticosteroid
fluticasone propionate is now available over the
counter (OTC) as Flonase Allergy Relief (GSK) in
the same strength as the prescription product
(Flonase, and generics) for patients ≥4 years old with
seasonal or perennial allergic rhinitis. It is the second
corticosteroid nasal spray to become available OTC;
triamcinolone acetonide (Nasacort Allergy 24HR) was
the first. Unlike prescription Flonase, the OTC product
is FDA-approved for reduction of ocular as well as
nasal symptoms. Brand-name prescription Flonase
has been...
Edoxaban (Savaysa) - The Fourth New Oral Anticoagulant
The Medical Letter on Drugs and Therapeutics • Mar 30, 2015 (Issue 1465)
Excretion 50% unchanged in urine
The Medical Letter ® Vol. 57 (1465) March 30, 2015
no fatal intracranial ...
The FDA has approved edoxaban (Savaysa – Daiichi
Sankyo), a once-daily, oral, direct factor Xa inhibitor,
for treatment of venous thromoboembolism (VTE)
and for prevention of stroke and systemic embolism
in patients with nonvalvular atrial fibrillation. It is the
fourth new oral anticoagulant to be approved for VTE
and nonvalvular atrial fibrillation.
Secukinumab (Cosentyx) for Psoriasis
The Medical Letter on Drugs and Therapeutics • Mar 30, 2015 (Issue 1465)
et al. N Engl J Med 2014; 371:326.
46
The Medical Letter ® Vol. 57 (1465) March 30, 2015
ADVERSE ...
Secukinumab (Cosentyx – Novartis), an injectable
human interleukin (IL)-17A antagonist, has been
approved by the FDA for treatment of moderate to
severe plaque psoriasis in adult patients who are
candidates for systemic therapy or phototherapy.
It is the first IL-17 inhibitor to be approved for any
indication in the US.